Given GBP1’s ability to promote programmed cell death, use of the specific GBP1:PIM1 interaction inhibitor (21) is a promising way to chemically activate GBP1, with implications for innate immunity and cancer therapy.Innate immune mechanisms that can cause cellular damage must be carefully regulated to ensure protection of bystander cells. This evidence concerns the gene GBP1 and cancer.